Drug Search Results
More Filters [+]

Lercanidipine

Alternative Names: lercanidipine, zanidip
Latest Update: 2024-03-07
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: Calcium Channel Blocker

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: LG
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Lercanidipine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Hypertension|Other

Phase 2: Hypertension

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

BAR-MEDS Lercanidipine

N/A

Recruiting

Obesity, Morbid

2026-10-01

ChiCTR2200059596

N/A

Not yet recruiting

Glioblastoma

2024-12-31

CTR20201599

N/A

Completed

Hypertension

2020-09-19

CTR20190309

N/A

Completed

Hypertension

2019-06-17

Recent News Events